The effect of alpha-1-antitrypsin on the progression of covid-19 disease

Phase 3

• Conditions: covid-19.; COVID-19; U07.1

• Registration Number: IRCT20110510006431N6
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age above 18 years
The presence of shortness of breath
Positive PCR test for corona or lung involvement in imaging
Signing informed consent and readiness to participate in the plan

Exclusion Criteria

Patients suffering from underlying diseases including pulmonary hypertension, kidney failure, seizures, depression, chronic hepatitis, cirrhosis and cholestatic liver diseases and pulmonary embolism (in the past 3 months)
Use of anti-coagulant drugs such as warfarin, hormonal drugs and other illegal drugs (within the past 30 days)
Alcohol consumption
Pregnancy or breastfeeding
Allergy to AAT drug
Having IgA deficiency
No smoking in the last 6 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The ratio of neutrophils to lymphocytes. Timepoint: At the first and at the 4th week of the study. Method of measurement: immunoassay.;ESR. Timepoint: At the first and at the 4th week of the study. Method of measurement: Westergren method and ESR tube.;CRP. Timepoint: At the first and at the 4th week of the study. Method of measurement: Spectrophotometry.;IL-6. Timepoint: At the first and at the 4th week of the study. Method of measurement: immunoassay.;Mortality rate. Timepoint: the 4th week of the study. Method of measurement: observation.;Hospitalization time. Timepoint: the 4th week of the study. Method of measurement: observation.